PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
Opdualag
Composition
- Active ingredients
- NIVOLUMAB 240MG; RELATLIMAB-RMBW 80MG
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application BLA761234.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Opdualag
- Active substance
- nivolumab
- Drug class
- PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, Combinations of monoclonal antibodies and antibody drug conjugates
- Route
- Intravenous
- Dosage form
- Solution
- Applicant
- Bristol Myers Squibb
- Status
- Prescription
- FDA approval
- 18 Mar 2022